The A, B, Cs of viral hepatitis in the biologic era

Current Opinion in Rheumatology

Volumn 22, Issue 4, 2010, Pages 443-450

  Ferri, Clodoveo ^a   Govoni, Marcello ^b   Calabrese, Leonard ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anti CD20 rituximab; Arthritis; Biologics; Cryoglobulinemia; HBV; HCV; Hepatitis B; Hepatitis C; Rheumatoid arthritis; TNF blockers

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ENTECAVIR; ETANERCEPT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; RIBAVIRIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTHRITIS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HEPATITIS C; HUMAN; INFECTION PREVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SERUM SICKNESS; VIRUS CARRIER; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; RECEPTORS, TUMOR NECROSIS FACTOR; RIBAVIRIN;

EID: 77953478225     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328338f6df     Document Type: Review

References (80)

1. Chen YF, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10:iii-iv; xi-xiii, 1-229.
2. Desai SB, Furst DE. Problems encountered during antitumor necrosis factor therapy. Best Pract Res Clin Rheumatol 2006; 20:757-790.
3. Ellerin T, Hurtado R, Lockamn S, Baden L Infections and antitumor necrosis factor alpha therapy. Arthritis Rheum 2003; 48:3013-3022.
4. Haroon N, Inman RD. Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21:397-403.
5. Vassilopoulos D, Calabrese LH. Risk of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infection. Curr Opin Rheumatol 2007; 19:619-625.
6. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006; 45:1294-1297.
7. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49 (5 Suppl): S13-S21.
8. Dienstag JL Hepatitis B virus infection. N Engl J Med 2008; 359:1486-1500.
9. Marcellin P. Hepatitis B and hepatitis C in 2009. Liver Int 2009; 29:1-8.
10. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
11. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209-220.
12. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65:983-989.
13. Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28:787-791.
14. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008; 27:1069-1071.
15. Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology (Oxford) 2009; 48:448-450.
16. Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following antitumor necrosis factor-alpha therapy. J Rheumatol 2009; 36:2416-2420.
17. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl 2):ii18-ii24.
18. Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31:107-109.
19. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35:421-424.
20. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53:1363-1365.
21. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12:974-976.
22. ZingarelliS, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-a-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009; 36:1188-1194.
23. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62:686-687.
24. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-1625.
25. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005; 52:2519-2520.
26. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28:718-720.
27. Vassilopoulos D, Manolakopoulos S. Rheumatic manifestations of hepatitis. Curr Opin Rheumatol 2010; 22:91-96.
28. Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10:701-702.
29. Wendling D, Auge B, Betinger D, et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005; 64:788-789.
30. Ueno Y, Tanaka S, Shimamoto M. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005; 50:163-166.
31. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 4:508-509.
32. Sakellariou GT, Chatzigiannis I. Long-term anti-TNF alpha therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007; 26:950-952.
33. OjiroK, NaganumaM, EbinumaH, et al. Reactivation of hepatitis Bin a patientwith Crohn's disease treated using infliximab. J Gastroenterol 2008; 43:397-401.
34. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008; 14:245-246.
35. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38:208-217.
36. Kim YJ, Bae SC, Sung YK, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol First Release 2009. doi: 10.3899/jrheum.090436.
37. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59:762-784.
38. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69 (Suppl 1):i2-i29.
39. Zingarelli S, Airo P, Frassi M, et al. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008; 60:22-27
40. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B.J Hepatol 2009;50:227-242.
41. Lok ASF, McMahon BJ. AASLD Practice Guidelines. Chronic hepatitis B: update 2009. Available at www.aasld.org.
42. Kaser TH, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int 2006; 26:1029-1039.
43. Larrea E, Garcia N, Qian C, et al. J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23:210-217.
44. Kinnman N, Andersson U, Hultcrantz R. In situ expression of transforming growth factor-beta1-3, latent transforming growth factor-beta binding protein and tumor necrosis factor-alpha in liver tissue from patients with chronic hepatitis C. Scand J Gastroenterol 2000; 35:1294-1300.
45. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005; 42:315-322.
46. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62:1078-1082.
47. Parke FA, Reveille JD. Antitumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51:800-804.
48. Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17:290-293.
49. Aslanidis S, VassiliadisT, Pyrpasopoulou A, et al. Inhibition of TNFalphadoes not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007; 26:261-264.
50. Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007; 46:97-99.
51. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006; 54:361-362.
52. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 2004; 51:580-584.
53. Ferri C, Ferraccioli GF, Ferrari D, et al. Safety of anti-tumor necrosis factor-a therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35:1944-1949
54. Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C.J Gastroenterol 2000; 35:221-225.
55. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etaner-cept in six patients with chronic hepatitis C infection and systemic auto immune diseases. Autoimmun Rev 2008; 8:104-106
56. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282-1288.
57. Giannitti C, Benucci M, Caporali R, et al. Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 2009;22:543-546.
58. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009; 38:265-280.
59. Caporali R, Caprioli M, Bobbio-Pallavicini F, et al. Long term treatment of • rheumatoid arthritis with rituximab. Autoimmun Rev 2009; 8:591-594.
60. Cacoub P, Delluc A, Saadoun A, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008; 67:283-287
61. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology (Oxford) 2006; 45:842-846.
62. De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007; 39 (Suppl 1): S122-S128.
63. Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003; 101:3818-3826.
64. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101:3827-3834.
65. Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with Peginterferon-ribavirin in refractory hepatitis Cvirus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008; 67:1431-1436.
66. Terrier B, Saadoun D, Sene D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus related vasculitis: a long-term follow-up study of thirty-two patients. Arthritis Rheum 2009; 60:2531-2540.
67. Sene D, Ghillani-Dalbin P, AmouraZ, et al. Rituximab may form a complex with IgM K mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009; 60:3848-3855
68. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717-1718.
69. Tsutsumi Y, Kanamori H, Mori A, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005; 4:599-608.
70. Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009; 8:223-235.
71. Pyrpasopoulou A, Douma S, Vassiliadis T, et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2009 [Epub ahead of print]. doi: 10.1007/s00296-009-1 202-212
72. Rodŕguez-Escalera C, Fernandez-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology (Oxford) 2008; 47:1732-1733.
73. Cacoub P, Terrier B. Hepatitis B-related autoimmune manifestations. Rheum Dis Clin North Am 2009; 5:125-137;
74. Guillevin L, Mahr A, Callard P, et al., French Vasculitis Study Group. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313-322.
75. Degertekin B, Lok AS. Indications for therapy in hepatitis B. Hepatology 2009; 49 (5 Suppl):S129-S137.
76. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39:397-408.
77. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare Dis 2008; 3:25.
78. Ferri C, Antonelli A, MasciaMT, et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome [review]. Dig Liver Dis 2007; Suppl:S59-S67.
79. Buskila D. Hepatitis C associated arthritis. Curr Opin Rheumatol 2000; 12:295-299.
80. Palazzi C, Olivieri I, Cacciatore P, et al. Management of hepatitis C virus-related arthritis. Expert Opin Pharmacother 2005; 6:27-34.